MEDICAMENT CONTAINING AN EFFECTOR OF THE GLUTATHIONE METABOLISM TOGETHER WITH ALPHA-LIPOIC ACID FOR IMMUNOMODULATION, IMMUNOSTIMULATION AND/OR ANTIPHLOGISTIC TREATMENT

A new medicament (A) for treating thiol-disulfide status disorders in diabetes mellitus comprises a glutathione metabolism effector (I) and alpha -lipoic acid (II) (both optionally in salt and/or prodrug form), as a combination preparation for simultaneous, separate or successive administration. Ind...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MICHAEL TAEGER, GERHARD FRIES, SIEGFRIED ANSORGE, DIETER KOEGST
Format: Patent
Sprache:eng ; por
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A new medicament (A) for treating thiol-disulfide status disorders in diabetes mellitus comprises a glutathione metabolism effector (I) and alpha -lipoic acid (II) (both optionally in salt and/or prodrug form), as a combination preparation for simultaneous, separate or successive administration. Independent claims are also included for the use of (I) together with (II) for the preparation of a medicament for treating thiol-disulfide status disorders, as immunomodulator and/or defense mechanism stimulant or as antiinflammatory agent, all for combating diabetes mellitus. ACTIVITY : Antidiabetic; Immunomodulator; Antiinflammatory. MECHANISM OF ACTION : Thiol-disulfide status regulator; glutathione metabolism effector; Angiotensin converting enzyme (ACE) inhibitor; Antioxidant; Free radical scavenger. When peripheral immune cells were cultured under thiol-deficient conditions, optionally in presence of captopril (Ia) and/or (II), the intracellular thiol expression (in mfi(Beads/Ratio)) (initially 2.88) after 14 days was 0.65 in controls (without addition of (Ia) or (II)), 1.83 in presence of 50 MicroM (II), 0.75 in presence of 10 MicroM (Ia) or 2.86 in presence of 50 MicroM (II) plus 10 MicroM (Ia).